CompletedPhase 1NCT02746237

Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585

Studying Drug- or toxin-induced pulmonary arterial hypertension

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Karos Pharmaceuticals
Principal Investigator
Carlos Sanabria, MD
Spaulding Clinical
Intervention
KAR5585 Capsules(drug)
Enrollment
120 enrolled
Eligibility
18-65 years · All sexes
Timeline
20152016

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02746237 on ClinicalTrials.gov

Other trials for Drug- or toxin-induced pulmonary arterial hypertension

Additional recruiting or active studies for the same condition.

See all trials for Drug- or toxin-induced pulmonary arterial hypertension

← Back to all trials